New Indication: Lorlatinib for first-line ALK-positive NSCLC
|New Indication: Lorlatinib for first-line ALK-positive NSCLC|
N Engl J Med 2020;383:2018-29.
Shaw AT, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancerhttps://doi.org/10.1056/NEJMoa2027187
Altai Chemo Planner
Quickly Prepare Accurate Chemotherapy Orders
Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.